Investing.com -- TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech company completed its $600 million acquisition of Ambry Genetics.
The brokerage said the deal accelerates Tempus' path to profitability, with Ambry expected to generate more than $40 million in EBITDA in 2024. The acquisition also expands Tempus' database by integrating Ambry’s germline testing business, creating new product opportunities and potential synergies.
“The deal affords TEM profitable germline testing lab, offers opportunities to enhance TEM's existing products, expand into new areas&provides path to positive free cash flow, w/ the main drawback Ambry's slower growth,” analyst at TD said, highlighting a larger revenue base&attractive growth/margin expansion.
However, TD Cowen noted that Ambry's long-term revenue growth of about 20% per year is below Tempus' standalone growth rate, slightly diluting its overall expansion trajectory. The deal also brings integration and execution risks.
Ambry, a 25-year-old genetics testing firm, is expected to generate over $300 million in revenue this year, with growth boosted by market share gains following Invitae’s bankruptcy.
Related Articles
TD Cowen reinstates coverage on Tempus AI with 'buy' after Ambry deal
Parker-Hannifin ratings upgraded by Moody's, positive outlook maintained
Japan Airlines jet wing strikes Delta Air plane on ground in Seattle
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。